Interleukin-1 (IL-1) inhibitors are second-line drugs for GA, including direct inhibitors of interleukin-1 beta (IL-1β) (canakinumab and gevokizumab), selective inhibitors of IL-1 receptors (anakinra), and IL-1β receptor antagonist (rilonacept), but treatment-induced adverse reactions, especially those related to upper respiratory tract infections, abscesses, and gastrointestinal diseases, are still unavoidable [7]. The gene discussed is IL1B; the disease is abscess.